A great deal of research is underway to develop knowledge in the fight against bladder cancer; new studies are being established, and new treatments are being offered.
There are exciting scientific discussions and new clinical trials of immunotherapy and targeted therapy drugs.
Immunotherapy alerts our immune system to cancer cells that are trying to hide from white blood cells. Immunotherapy drugs that are currently authorised or in clinical trials for bladder cancer include: atezolizumab (Tecentriq®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), durvalumab (Imfinzi®), and avelumab (Bavencio®). Some of these drugs are currently funded by the NHS, and some are only available as part of a research study or clinical trial. Your doctor might ask you to have a PD-L1 test to decide if you could receive immunotherapy.
Targeted therapies are drugs that block the growth of cancers by acting on specific weaknesses in some cancer cells. Targeted therapies that are currently in clinical trials for bladder cancer include include erdafitinib (Balversa®) and enfortumab vedotin (Padcev®). Neither of these drugs are yet available on the NHS. Your doctor might ask you to have an FGFR test to decide if you would benefit from a targeted therapy as part of a clinical trial.
If you have non-muscle invasive bladder cancer - ask your doctor:
If you have advanced cancer, metastatic cancer, or muscle-invasive bladder cancer - ask your doctor:
You can also print out our complete list of clinical trials that are currently recruiting bladder cancer patients in the UK, and bring it with you to discuss with your doctor.
We’ve done everything we can to make all the information on this site as accurate as possible. Whilst we have had support from a small team of medical professionals advisors to review the general medical content of this site, please remember, that only YOUR medical team can give YOU specific advice about YOUR symptoms or illness. We encourage you to discuss any potential options with them.